Miniatura

Fitxers

894421.pdf (1.3 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-03-01

Llicència de publicació

cc-by-nc-nd (c) Bosch Barrera, Joaquim et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/221352

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.lungcan.2025.108105

Resum

Background: Advanced squamous non-small cell lung cancer (sq-NSCLC) has long relied on chemotherapy and, more recently, on its combination with PD-1 immunotherapy. Ibrilatazar (ABTL0812) is an innovative oral agent that induces cytotoxic autophagy selectively in cancer cells. In the ENDOLUNG trial we have evaluated the efficacy and safety of ibrilatazar combined with chemotherapy in sq-NSCLC patients. Methods: Patients with stage III/IV sq-NSCLC received ibrilatazar (1300 mg tid) alongside paclitaxel (175 mg/m2) and carboplatin (AUC 5) every 3 weeks for up to 8 cycles, followed by ibrilatazar maintenance until progression or toxicity. Primary endpoint was overall response rate (ORR) per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Results: 40 patients were enrolled constituting the intention-to-treat (ITT) population (90 % male, median age 66, ECOG 0-1). The efficacy analysis (FA) subset included 25 patients, excluding 15 patients without a measurement of the primary variable. For ITT and FA populations, the ORR was 32.5 % (95 % Confidence Interval (CI) 21.3-50.1) vs 52.0 % (95 % CI 34.2-65.9), the disease control rate (DCR) was 52.5 % (95 % CI: 36.1-68.5) vs 84.0 % (95 % CI: 63.9-95.5), the PFS was identical (6.2 months; 95 % CI: 4.4-8.8) and the OS was 18.4 months (95 % CI: 9.5-NC) and 22.5 months (95 % CI: 10.4-NC), respectively. Most common adverse events included asthenia (62.5 %), diarrhea (45.0 %), nausea (37.5 %), anemia (32.5 %) and neutropenia (27.5 %). Pharmacokinetic and pharmacodynamic data confirmed ibrilatazar activity. Conclusions: Ibrilatazar combined with paclitaxel and carboplatin shows promising efficacy and safety in sq-NSCLC, warranting further clinical development.

Matèries

Càncer de pulmó, Autofàgia, Quimioteràpia del càncer, Tumors

Matèries (anglès)

Lung cancer, Autophagy, Cancer chemotherapy, Tumors

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

BOSCH BARRERA, Joaquim, ESTÉVEZ-GARCÍA, Purificación, MARTÍN-MARTORELL, Paloma, SABATIER, Renaud, NADAL, Ernest, SAIS, Elia, GASCÓN, Pere, OAKNIN, Ana, RODON, Jordi, LIZCANO, José miguel, MUÑOZ GUARDIOLA, Pau, FIERRO-DURÁN, Gemma, PEDRÓS-GÁMEZ, Oriol, PÉREZ-MONTOYO, Hector, YESTE VELASCO, Marc, CORTAL, Marc, PÉREZ-CAMPOS, Antonio, ALFÓN, José, DOMÈNECH, Carles, MORAN, Teresa. ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer. _Lung Cancer_. 2025. Vol. 201. [consulta: 21 de gener de 2026]. ISSN: 0169-5002. [Disponible a: https://hdl.handle.net/2445/221352]

Exportar metadades

JSON - METS

Compartir registre